

CITATION REPORT

List of articles citing

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update

DOI: 10.1016/j.numecd.2013.05.002

Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 799-807.

Source: <https://exaly.com/paper-pdf/54953880/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
99	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. <i>Atherosclerosis</i> , 2013 , 231, 300-7	3.1	49
98	Prevalence and types of persistent dyslipidemia in patients treated with statins. <i>Croatian Medical Journal</i> , 2013 , 54, 339-45	1.6	25
97	Combined REDV Polypeptide and Heparin onto Titanium Surface for the Hemocompatibility and Selectively Endothelialization. <i>Journal of Cell Science & Therapy</i> , 2014 , 06,		1
96	Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. <i>Cardiovascular Diabetology</i> , 2014 , 13, 135	8.7	33
95	Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia. <i>Circulation Research</i> , 2014 , 114, 233-5	15.7	20
94	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014 , 13, 26	8.7	124
93	Effects of lipids and lipoproteins on diabetic foot in people with type 2 diabetes mellitus: a meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 559-64	3.2	17
92	Prevalence of atherogenic dyslipidemia: association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study. <i>Atherosclerosis</i> , 2014 , 235, 562-9	3.1	17
91	Resistance and intolerance to statins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 1057-66	6.5	132
90	Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects. <i>Clinical Therapeutics</i> , 2014 , 36, 967-73	3.5	8
89	A comparison of European and US guidelines for familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015 , 26, 215-20	4.4	10
88	Recent developments in modulating atherogenic lipoproteins. <i>Current Opinion in Lipidology</i> , 2015 , 26, 369-75	4.4	6
87	Practical Application of Antidiabetic Efficacy of Lycium barbarum Polysaccharide in Patients with Type 2 Diabetes. <i>Medicinal Chemistry</i> , 2015 , 11, 383-90	1.8	63
86	Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?. <i>Cardiology</i> , 2015 , 131, 225-7	1.6	13
85	Management of patients with familial hypercholesterolaemia. <i>Nature Reviews Cardiology</i> , 2015 , 12, 565-74	14.8	79
84	Dan-Qi prescription ameliorates insulin resistance through overall corrective regulation of glucose and fat metabolism. <i>Journal of Ethnopharmacology</i> , 2015 , 172, 70-9	5	21
83	Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents. <i>European Journal of Medicinal Chemistry</i> , 2015 , 102, 487-529	6.8	103

82	Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015 , 22, 119-25	4	61
81	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015 , 19, 1-12	1.7	50
80	Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016 , 23, 145-9	4	9
79	Relationship between serum triglyceride levels and endothelial function in a large community-based study. <i>Atherosclerosis</i> , 2016 , 249, 70-5	3.1	23
78	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016 , 18, C2-C12	1.5	56
77	Current and future trends in the lipid lowering therapy. <i>Pharmacological Reports</i> , 2016 , 68, 737-47	3.9	16
76	Probucol normalizes cholesteryl ester transfer in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2016 , 116, 29-35	7.4	1
75	Apoprotein C-III: A review of its clinical implications. <i>Clinica Chimica Acta</i> , 2016 , 460, 50-4	6.2	12
74	Hepatotoxicity and endothelial dysfunction induced by high choline diet and the protective effects of phloretin in mice. <i>Food and Chemical Toxicology</i> , 2016 , 94, 203-12	4.7	35
73	Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. <i>Atherosclerosis</i> , 2016 , 246, 243-50	3.1	121
72	Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study. <i>Atherosclerosis</i> , 2016 , 249, 116-24	3.1	42
71	[Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy]. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2016 , 28, 87-93	1.4	4
70	Celecoxib for the treatment of atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 619-33	5.9	11
69	Sleep duration and smoking are associated with coronary heart disease among US adults with type 2 diabetes: Gender differences. <i>Diabetes Research and Clinical Practice</i> , 2017 , 124, 93-101	7.4	8
68	Baccaurea angulata fruit juice ameliorates altered hematological and biochemical biomarkers in diet-induced hypercholesterolemic rabbits. <i>Nutrition Research</i> , 2017 , 42, 31-42	4	11
67	Triglycerides Revisited to the Serial. <i>Advances in Clinical Chemistry</i> , 2017 , 80, 1-44	5.8	3
66	Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2017 , 33, 1-5	3.5	88
65	Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. <i>Pharmacological Research</i> , 2017 , 122, 53-65	10.2	49

64	Similarities and differences between coronary heart disease and stroke in the associations with cardiovascular risk factors: The Japan Collaborative Cohort Study. <i>Atherosclerosis</i> , 2017 , 261, 124-130	3.1	14
63	Hypertriglyceridaemia and risk of coronary artery disease. <i>Nature Reviews Cardiology</i> , 2017 , 14, 401-411	14.8	178
62	Prediction of Cardiovascular Disease by the Framingham-REGICOR Equation in the High-Risk PREDIMED Cohort: Impact of the Mediterranean Diet Across Different Risk Strata. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	11
61	The application of atherogenic dyslipidaemia consensus recommendations in the primary care setting. DAT-AP study. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017 , 29, 178-184	1.4	0
60	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017 , 29, 168-177	1.4	5
59	[PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know]. <i>Hipertension Y Riesgo Vascular</i> , 2017 , 34, 176-183	0.5	0
58	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017 , 29, 168-177	0.3	1
57	The application of atherogenic dyslipidaemia consensus recommendations in the primary care setting. DAT-AP study. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017 , 29, 178-184	0.3	
56	Fibrates in the management of atherogenic dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 913-921	2.5	29
55	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. <i>Current Atherosclerosis Reports</i> , 2017 , 19, 62	6	31
54	Chemical characteristics of an Ilex Kuding tea polysaccharide and its protective effects against high fructose-induced liver injury and vascular endothelial dysfunction in mice. <i>Food and Function</i> , 2017 , 8, 2536-2547	6.1	30
53	Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. <i>International Journal of Cardiology</i> , 2017 , 248, 355-360	3.2	5
52	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017 , 7, 45-51	2.6	35
51	Association between fasting Triglyceride levels and the Prevalence of Asymptomatic Intracranial Arterial Stenosis in a Chinese Community-based Study. <i>Scientific Reports</i> , 2018 , 8, 5744	4.9	4
50	Interaction of lecithin:cholesterol acyltransferase with lipid surfaces and apolipoprotein A-I-derived peptides. <i>Journal of Lipid Research</i> , 2018 , 59, 670-683	6.3	8
49	The "T" allele of apolipoprotein A5 rs2075291 is significantly associated with higher total cholesterol and triglyceride and lower high-density lipoprotein cholesterol levels in Asians: a meta-analysis. <i>Nutrition Research</i> , 2018 , 56, 11-22	4	1
48	Improvement of endothelial function by pitavastatin: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 279-286	4	21
47	Non-HDL-C goals based on the distribution of population percentiles in ELSA-Brasil: Is it time to change?. <i>Atherosclerosis</i> , 2018 , 274, 243-250	3.1	3

46	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. <i>Korean Circulation Journal</i> , 2018 , 48, 1097-1119	2.2	10
45	Association of Serum Triglycerides With Arterial Stiffness in Subjects With Low Levels of Low-Density Lipoprotein Cholesterol. <i>Circulation Journal</i> , 2018 , 82, 3052-3057	2.9	5
44	Benefits and risks of the treatment with fibrates--a comprehensive summary. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 1099-1112	3.8	17
43	Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 1852-1860	3.9	14
42	CRISPR/Cas9-mediated knockout suppresses plasma triglyceride concentrations and adiposity in rats. <i>Journal of Lipid Research</i> , 2018 , 59, 1575-1585	6.3	22
41	High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes. <i>Atherosclerosis</i> , 2019 , 282, 183-187	3.1	3
40	Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019 , 26, 263-272	2.9	3
39	Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). <i>BMC Public Health</i> , 2019 , 19, 1500	4.1	47
38	Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARM) Pemaifibrate. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	14
37	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019 , 290, 140-205	3.1	259
36	Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. <i>Diabetes Care</i> , 2019 , 42, 2307-2314	14.6	21
35	New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. <i>Cardiovascular Diabetology</i> , 2019 , 18, 80	8.7	55
34	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020 , 41, 111-188	9.5	2236
33	Triglycerides are related to left ventricular mass in hypertensive patients independently of other cardiometabolic risk factors: the effect of gender. <i>Scientific Reports</i> , 2020 , 10, 13253	4.9	2
32	Cholesteryl ester transfer protein inhibitors in precision medicine. <i>Clinica Chimica Acta</i> , 2020 , 510, 733-740	4.0	2
31	Acupuncture treatment for carotid atherosclerotic plaques: study protocol for a pilot randomized, single blinded, controlled clinical trial. <i>Trials</i> , 2020 , 21, 768	2.8	2
30	Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020 , 19, 208	8.7	16
29	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 361-379	8.1	36

28	Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial. <i>Atherosclerosis</i> , 2020 , 305, 34-41	3.1	5
27	Non-HDL cholesterol series: PCSK9 inhibitor new season!. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1661-1662	3.9	
26	Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 175-180	2.5	5
25	Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women. <i>Nutrients</i> , 2020 , 12,	6.7	66
24	Comprehensive plaque assessment with serial coronary CT angiography: translation to bedside. <i>International Journal of Cardiovascular Imaging</i> , 2020 , 36, 2335-2346	2.5	5
23	What is New in the Most Recent Guidelines for the Management of Dyslipidemias of the European Society of Cardiology and the European Atherosclerosis Society?. <i>Cardiologia Croatica</i> , 2021 , 16, 87-95	0	
22	The triglyceride to HDL-cholesterol ratio and chronic graft failure in renal transplantation. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 301-310	4.9	1
21	Plasma Amino Acids and Residual Hypertriglyceridemia in Diabetic Patients Under Statins: Two Independent Cross-Sectional Hospital-Based Cohorts. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 605716	5.4	0
20	Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2021 , STROKEAHA121034593	6.7	2
19	Assessment of medical intern knowledge, awareness and practice of familial hypercholesterolemia at academic institutes in Jeddah, Saudi Arabia. <i>Lipids in Health and Disease</i> , 2020 , 19, 101	4.4	2
18	Treatment of hypertriglyceridemia: a review of current options. <i>Physiological Research</i> , 2015 , 64, S331-40.	4.1	18
17	Residual Cardiovascular Risk Factors in Dyslipidemia.		
16	Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 78, 885-890	3.1	
15	Interaction of lecithin-cholesterol acyltransferase with lipid surfaces and apolipoprotein A-I derived peptides: implications for the cofactor mechanism of apolipoprotein A-I.		
14	Original paper: A new type of polyphenols-containing dietary supplement for correction of lipids and inflammatory markers in patients with coronary artery disease. <i>Seminars in Cardiovascular Medicine</i> , 2018 , 24, 22-28	0	
13	Model-based Cost-effectiveness Analysis of Atorvastatin Drugs for Prevention of Cardiovascular Diseases in Iran. <i>International Journal of Preventive Medicine</i> , 2020 , 11, 57	1.6	2
12	Synthesis of N-arylmethyl Substituted Indole Derivatives as New Antiplatelet Aggregation Agents. <i>Iranian Journal of Pharmaceutical Research</i> , 2014 , 13, 35-42	1.1	3
11	Biochemical risk factors of atherosclerotic cardiovascular disease: From a narrow and controversial approach to an integral approach and precision medicine.. <i>Expert Review of Cardiovascular Therapy</i> , 2021 ,	2.5	

10	Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	0
9	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.. <i>Atherosclerosis</i> , 2021 , 343, 28-50	3.1	4
8	Non-HDL cholesterol paradox and effect of underlying malnutrition in patients with coronary artery disease: A 41,182 cohort study.. <i>Clinical Nutrition</i> , 2022 , 41, 723-730	5.9	0
7	Achieving coronary plaque regression: a decades-long battle against coronary artery disease.. <i>Expert Review of Cardiovascular Therapy</i> , 2022 ,	2.5	0
6	ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.. <i>Current Atherosclerosis Reports</i> , 2022 ,	6	0
5	Coronary Computed Tomography Angiography Evaluation of Plaque Morphology and its Relationship to HDL and Total Cholesterol to HDL Ratio. <i>Journal of Clinical Lipidology</i> , 2022 ,	4.9	1
4	Use of fibrates is not associated with reduced risks of mortality or cardiovascular events among ESRD patients: A national cohort study. 9,		0
3	The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population. 10,		0
2	A New Antidiabetic Agent Showing Short- and Long-Term Effects Due to Peroxisome Proliferator-Activated Receptor Alpha/Gamma Dual Agonism and Mitochondrial Pyruvate Carrier Inhibition. 2023 , 66, 3566-3587		0
1	HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS. 2023 , 24, 5391		0